Logo.png
GRI Bio to Present at the 8th Annual IPF Summit
01 juil. 2024 08h45 HE | GRI Bio, Inc.
LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
Logo.png
GRI Bio Announces Closing of $4.0 Million Public Offering
28 juin 2024 16h05 HE | GRI Bio, Inc.
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
Logo.png
GRI Bio Announces Reverse Stock Split
26 janv. 2024 08h05 HE | GRI Bio, Inc.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
Logo.png
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
15 nov. 2023 08h05 HE | GRI Bio, Inc.
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are...
Logo.png
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
13 juin 2023 08h35 HE | GRI Bio, Inc.
Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc....
logo.png
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event
27 avr. 2023 09h05 HE | GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Wednesday, May 3rd at 2:00 PM ET LA JOLLA, CA, April 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or...